CSPC Pharmaceutical (1093.HK) — Upcoming Catalysts

FDA PDUFA dates, advisory-committee meetings, and Phase 2/3 readout windows for CSPC Pharmaceutical, built from public data lanes (ClinicalTrials.gov and official sources). Each row links to its source.

For informational purposes only — not investment advice. Track 1093.HK live on Mooboard →

This week2

  • Sep 30, 2026
    CSPC Pharmaceutical(1093.HK)Phase 2/3 readout
    Dextromethorphan and Bupropion Sustained-Release Tablets · Phase 3 · Major Depressive Disorder (MDD)
    NCT06958692: A Trial of Dextromethorphan and Bupropion Sustained-Release Tablets in Patients With Major Depressive Disorder. Primary completion 2026-09-30 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Oct 2026
    CSPC Pharmaceutical(1093.HK)Phase 2/3 readout
    Sirolimus for Injection (Albumin-bound) · Phase 3 · HR+/HER2- Advanced/Metastatic Breast Cancer
    NCT06929325: Sirolimus for Injection (Albumin-bound) Combined With Fulvestrant for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Previously Treated With CDK4/6 Inhibitors. Primary completion 2026-10 (estimated); status NOT_YET_RECRUITING.
    ClinicalTrials.gov ↗

Next 30 days2

  • Oct 8, 2026
    CSPC Pharmaceutical(1093.HK)Phase 2/3 readout
    Hydroxocobalamin Chloride Injection · Phase 3 · Methylmalonic Acidemia (MMA)
    NCT07163364: A Study to Evaluate the Effects and Safety of Hydroxocobalamin in Participants With Combined Methylmalonic Academia (cblC Type). Primary completion 2026-10-08 (estimated); status NOT_YET_RECRUITING.
    ClinicalTrials.gov ↗
  • Oct 11, 2026
    CSPC Pharmaceutical(1093.HK)Phase 2/3 readout
    HB1801 · Phase 2 · Advanced Breast Cancer
    NCT07083505: A Study Comparing the Efficacy and Safety of HB1801 With Taxotere® in Advanced Breast Cancer. Primary completion 2026-10-11 (estimated); status NOT_YET_RECRUITING.
    ClinicalTrials.gov ↗

31–90 days3

  • Oct 30, 2026
    CSPC Pharmaceutical(1093.HK)Phase 2/3 readout
    Prusogliptin, Dapagliflozin(high dose), Dapagliflozin (low dose) placebo, plus metformin XR · Phase 3 · Type 2 Diabetes
    NCT07026968: A Study of Prusogliptin Tablets Combined With Dapagliflozin Tablets and Metformin Hydrochloride Extended Release Tablets in Type 2 Diabetes. Primary completion 2026-10-30 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Nov 30, 2026
    CSPC Pharmaceutical(1093.HK)Phase 2/3 readout
    SYS6010 · Phase 2 · Non-Small Cell Lung Cancer
    NCT07256509: A Study of SYS6010 Combined With Osimertinib Versus Osimertinib Alone as Neoadjuvant Therapy for Patients With EGFR Mutation-positive Resectable Non-squamous Non-small Cell Lung Cancer. Primary completion 2026-11-30 (estimated); status NOT_YET_RECRUITING.
    ClinicalTrials.gov ↗
  • Dec 12, 2026
    CSPC Pharmaceutical(1093.HK)Phase 2/3 readout
    SYS6010 · Phase 3 · NSCLC
    NCT07376382: A Phase Ⅲ Clinical Study of SYS6010 in Combination With Osimertinib in Patients With Locally Advanced or Metastatic NSCLC. Primary completion 2026-12-12 (estimated); status NOT_YET_RECRUITING.
    ClinicalTrials.gov ↗

Later18

  • Dec 25, 2026
    CSPC Pharmaceutical(1093.HK)Phase 2/3 readout
    Glumetinib tablets · Phase 2 · Locally Advanced/Recurrent or Distant Metastasized Non-small Cell Lung Cancer With MET Overexpression
    NCT06525350: A Study to Evaluate the Efficacy and Safety of the Combination of Glumetinib and Docetaxel（Albumin Bound）Verse Docetaxel for the Treatment of MET-overexpressed Non-small Cell Lung Cancer. Primary completion 2026-12-25 (estimated); status NOT_YET_RECRUITING.
    ClinicalTrials.gov ↗
  • Mar 10, 2027
    CSPC Pharmaceutical(1093.HK)Phase 2/3 readout
    A zoster mRNA vaccine SYS6017 · Phase 2 · Herpes Zoster
    NCT07354659: Immunogenicity and Safety of SYS6017 in the Participants Aged 40 Years and Above. Primary completion 2027-03-10 (estimated); status NOT_YET_RECRUITING.
    ClinicalTrials.gov ↗
  • Mar 28, 2027
    CSPC Pharmaceutical(1093.HK)Phase 2/3 readout
    SYS6041 · Phase 1 / Phase 2 · Advanced Solid Tumors
    NCT07744763: A Phase I/IIa Study of SYS6041 in Patients With Advanced Solid Tumors. Primary completion 2027-03-28 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Apr 2027
    CSPC Pharmaceutical(1093.HK)Phase 2/3 readout
    Docetaxel for Injection (Albumin-bound) · Phase 1 / Phase 2 · Locally Advanced Unresectable Esophageal Squamous Carcinoma
    NCT06136988: A Study of Docetaxel for Injection (Albumin-bound) and SG001 in Combination With Cisplatin and Simultaneous Radiotherapy for Locally Advanced Unresectable Esophageal Squamous Carcinoma.. Primary completion 2027-04 (estimated); status NOT_YET_RECRUITING.
    ClinicalTrials.gov ↗
  • Apr 28, 2027
    CSPC Pharmaceutical(1093.HK)Phase 2/3 readout
    SYHX1901 · Phase 3 · Moderate to Severe Plaque Psoriasis
    NCT06943950: A Phase III Study of SYHX1901 Tablets in the Treatment of Moderate to Severe Plaque Psoriasis. Primary completion 2027-04-28 (estimated); status NOT_YET_RECRUITING.
    ClinicalTrials.gov ↗
  • Apr 30, 2027
    CSPC Pharmaceutical(1093.HK)Phase 2/3 readout
    SYH2085 · Phase 2 · Influenza
    NCT07798193: A Study of SYH2085 Tablets Compared With Placebo in Chinese Adult Patients With Uncomplicated Influenza.. Primary completion 2027-04-30 (estimated); status NOT_YET_RECRUITING.
    ClinicalTrials.gov ↗
  • Apr 30, 2027
    CSPC Pharmaceutical(1093.HK)Phase 2/3 readout
    Glumetinib Tablets · Phase 2 · Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors
    NCT06947291: Safety and Efficacy of Glumetinib Combined With Docetaxel for Injection (Albumin-bound) in Patients With Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors. Primary completion 2027-04-30 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Apr 30, 2027
    CSPC Pharmaceutical(1093.HK)Phase 2/3 readout
    SYH2070 · Phase 2 · Mixed Hyperlipidemia
    NCT07695597: A Study of SYH2070 Injection in Participants With Mixed Hyperlipidemia. Primary completion 2027-04-30 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • May 31, 2027
    CSPC Pharmaceutical(1093.HK)Phase 2/3 readout
    SYHX1901 · Phase 2 · Severe Alopecia Areata
    NCT06562894: Study to Evaluate Safety and Efficacy of SYHX1901 Tablets in Severe Alopecia Areata Patients. Primary completion 2027-05-31 (estimated); status NOT_YET_RECRUITING.
    ClinicalTrials.gov ↗
  • Jun 15, 2027
    CSPC Pharmaceutical(1093.HK)Phase 2/3 readout
    SYS6010 jnjection · Phase 1 / Phase 2 · Advanced Solid Tumors; Breast Cancer
    NCT06775236: Clinical Trial of SYS6010±SYH2051 Versus Chemotherapy in Advanced Breast Cancer and Other Solid Tumors. Primary completion 2027-06-15 (estimated); status NOT_YET_RECRUITING.
    ClinicalTrials.gov ↗
  • Jun 30, 2027
    CSPC Pharmaceutical(1093.HK)Phase 2/3 readout
    Bempedoic Acid Tablet · Phase 3 · Primary Hyperlipidemia
    NCT07623915: A Clinical Study to Evaluate the Efficacy and Safety of Bempedoic Acid. Primary completion 2027-06-30 (estimated); status NOT_YET_RECRUITING.
    ClinicalTrials.gov ↗
  • Jul 1, 2027
    CSPC Pharmaceutical(1093.HK)Phase 2/3 readout
    CM326 dose 1 · Phase 2 · Chronic Obstructive Pulmonary Disease
    NCT07418736: A Phase II Study of CM326 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease. Primary completion 2027-07-01 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Jul 30, 2027
    CSPC Pharmaceutical(1093.HK)Phase 2/3 readout
    SYS6045 · Phase 1 / Phase 2 · Advanced Solid Tumors
    NCT07122063: Clinical Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SYS6045 in Patients With HER2-Positive, Expressing, or Mutated Advanced Malignant Solid Tumors. Primary completion 2027-07-30 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Aug 1, 2027
    CSPC Pharmaceutical(1093.HK)Phase 2/3 readout
    SYHX2008 injection · Phase 2 · Gastrointestinal Neuroendocrine Pancreatic Tumor
    NCT06505395: A Trial to Assess Efficacy, Safety, Pharmacokinetics of Octreotide Subcutaneous Injection in Patients With Gastroentero-pancreatic Neuroendocrine Tumor (GEP-NET). Primary completion 2027-08-01 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Sep 16, 2027
    CSPC Pharmaceutical(1093.HK)Phase 2/3 readout
    SYH2070 injection dose1 · Phase 2 · Diagnosed With HoFH
    NCT07591298: Phase II Clinical Trial to Evaluate the Efficacy and Safety of SYH2070 Injection in Participants With Homozygous Familial Hypercholesterolemia. Primary completion 2027-09-16 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Sep 28, 2027
    CSPC Pharmaceutical(1093.HK)Phase 2/3 readout
    SYH2069 Injection (group 1) · Phase 2 · T2DM (Type 2 Diabetes Mellitus)
    NCT07796477: A Study of SYH2069 Injection in Participants With T2DM Not Controlled With Diet/Exercise Alone or Metformin. Primary completion 2027-09-28 (estimated); status NOT_YET_RECRUITING.
    ClinicalTrials.gov ↗
  • Sep 30, 2027
    CSPC Pharmaceutical(1093.HK)Phase 2/3 readout
    SYS6010 injection · Phase 3 · Non-Small Cell Lung Cancer
    NCT07633873: SYS6010 Combined With Enlonstobart Versus Immunotherapy+ Platinum-based Chemotherapy for Patients With PD-L1-Positive Locally Advanced or Metastatic NSCLC（SYNSTAR 04）. Primary completion 2027-09-30 (estimated); status NOT_YET_RECRUITING.
    ClinicalTrials.gov ↗
  • Sep 30, 2027
    CSPC Pharmaceutical(1093.HK)Phase 2/3 readout
    SYH2069 Injection · Phase 2 · Overweight or Obesity
    NCT07803991: Efficacy and Safety of SYH2069 Injection in Obese Participants Without Diabetes.. Primary completion 2027-09-30 (estimated); status NOT_YET_RECRUITING.
    ClinicalTrials.gov ↗

How CSPC Pharmaceutical has moved — past-year price reactions

How binary is 1093.HK? Its typical daily move, how often it swings ±10%, and its biggest single-day moves over the last year — useful context for sizing around a catalyst.

1.7%
typical day (1Y)
2
±10% days
47.7%
annualized vol
245
trading days
Largest single-day moves
  • +13.8%2026-03-27no matched headline
  • -10.2%2026-01-30no matched headline
  • +9.6%2026-08-20no matched headline
  • +8.3%2026-07-02no matched headline
  • +8.1%2026-02-03no matched headline
  • +7.8%2026-05-29no matched headline

Real daily price moves over the past year — not every move is a catalyst, and headlines (where shown) are a possible same-day driver, not confirmed causation.

CSPC Pharmaceutical — active clinical pipeline

CSPC Pharmaceutical's registered Phase 1–3 programs by asset and indication, derived from ClinicalTrials.gov.

70 assets96 programsPh1 24Ph2 36Ph3 36
AreasOncologyAutoimmuneImmunologyMetabolicNeuroscienceCardiovascularInfectiousOther
SYS6010Oncology
Phase 2
Non-Small Cell Lung Cancer
Phase 3
EGFR-mutated Locally Advanced or Metastatic NSCLCHead and Neck Squamous Cell CarcinomaLocally Advanced/Metastatic/Recurrent ESCCNon-small Cell Lung Cancer (2)NSCLCRecurrent or Metastatic Breast Cancer
HB1801Oncology
Phase 2
Advanced Breast CancerHER2-positive Breast Cancer
Phase 3
HER2-Negative Advanced Breast Cancer
SYS6002Oncology
Phase 2
Advanced Urothelial Carcinoma
Phase 3
Cervical CancerUrothelial Carcinoma
SYS6043Oncology
Phase 2
Advanced Solid TumorsAdvanced/Metastatic Solid Tumors
Phase 3
Platinum-resistant Ovarian Cancer
CM310Immunology
Phase 3
Chronic Obstructive Pulmonary DiseaseModerate to Severe Asthma
Docetaxel for injection (Albumin-bound)Oncology
Phase 2
Locally Advanced Unresectable Esophageal Squamous Carcinoma
Phase 3
Gastric Cancer
DP303cOncology
Phase 3
HER2-positive Advanced Breast CancerHER2-positive Breast Cancer
Mitoxantrone Hydrochloride Liposome InjectionOncology
Phase 3
Peripheral T Cell LymphomaRecurrent Metastatic Nasopharyngeal Carcinoma
Sirolimus for injection (Albumin-bound)Oncology
Phase 2
Epithelioid Hemangioendothelioma
Phase 3
HR+/HER2- Advanced/Metastatic Breast Cancer
SYH2053 injectionMetabolic
Phase 3
Heterozygous Familial Hypercholesterolemia (HeFH)Non-familial Hypercholesterolemia and Mixed Hyperlipidemia
SYHX1901Autoimmune
Phase 2
Severe Alopecia Areata
Phase 3
Moderate to Severe Plaque Psoriasis
SYS6010 injectionOncology
Phase 2
Head and Neck Squamous Cell Carcinoma
Phase 3
Non-Small Cell Lung Cancer
AmmoxetineNeuroscience
Phase 3
Major Depressive Disorder (MDD)
Aprocitentan tablets(SYH9108)Cardiovascular
Phase 3
Resistant Hypertension
Bempedoic Acid TabletMetabolic
Phase 3
Primary Hyperlipidemia
CM326Immunology
Phase 3
Moderate to Severe Asthma
CM326 injectionImmunology
Phase 3
Chronic Rhinosinusitis With Nasal Polyps
Dextromethorphan and Bupropion Sustained-Release TabletsNeuroscience
Phase 3
Major Depressive Disorder (MDD)
Docetaxel for Injection (Albumin bound)Oncology
Phase 3
Advanced Pancreatic Cancer
Hydroxocobalamin Chloride InjectionOther
Phase 3
Methylmalonic Acidemia (MMA)
Liposomal IrinotecanOncology
Phase 3
Pancreatic Cancer
rhTNK-tPACardiovascular · PLAT
Phase 3
Acute Ischemic Stroke
Sirolimus for injection (albumin bound)Oncology
Phase 3
Gastroenteropancreatic Neuroendocrine Tumors
SYH9056Cardiovascular
Phase 3
Mild-to-moderate Essential Hypertension
SYHX2008Other
Phase 3
Diagnosed With Acromegaly, Currently in the Active Stage of the Disease
SYS6010+SG001+ physician's choice (Capecitabine or 5-FU)Oncology
Phase 3
Esophageal Squamous Cell Carcinoma
A zoster mRNA vaccine SYS6017Other
Phase 1
Herpes Zoster
Phase 2
Herpes Zoster
Glumetinib TabletsOncology
Phase 2
Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid TumorsLocally Advanced/Recurrent or Distant Metastasized Non-small Cell Lung Cancer With MET Overexpression
SYH2069 InjectionMetabolic
Phase 1
Overweight or Obesity
Phase 2
Overweight or Obesity
SYH2085Infectious
Phase 1
Infectious
Phase 2
Influenza
SYS6023Oncology
Phase 1
Advanced Solid Tumor
Phase 2
Advanced Breast Cancer
CM326 dose 1Other
Phase 2
Chronic Obstructive Pulmonary Disease
HA131Oncology
Phase 2
Advanced Hepatocellular Carcinoma (HCC)
JMT101Oncology
Phase 2
Head and Neck Squamous Cell Carcinoma
LetrozoleOncology · CYP19A1
Phase 2
HR+/HER2- Advanced/Metastatic Breast Cancer
sirolimus (albumin-bound)Oncology
Phase 2
Advanced Solid Tumors
SKLB1028 Dose EscalationOncology
Phase 2
Newly Diagnosed Acute Myeloid Leukemia (AML)
SYH2068 Dose 1Other
Phase 2
Adult Participants With Elevated Lipoprotein(a)
SYH2069 Injection (group 1)Metabolic
Phase 2
T2DM (Type 2 Diabetes Mellitus)
SYH2070Metabolic
Phase 2
Mixed Hyperlipidemia
SYH2070 injection dose1Other
Phase 2
Diagnosed With HoFH
SYHX2008 injectionOncology
Phase 2
Gastrointestinal Neuroendocrine Pancreatic Tumor
SYHX2011Oncology
Phase 2
Advanced Breast Cancer
SYS6006Oncology
Phase 2
Advanced Solid Tumors
SYS6010 jnjectionOncology
Phase 2
Advanced Solid Tumors
SYS6026Other
Phase 2
High-grade Cervical Intraepithelial Lesions
SYS6041Oncology
Phase 2
Advanced Solid Tumors
SYS6041, bevacizumabOncology
Phase 2
Ovarian Cancer
SYS6045Oncology
Phase 2
Advanced Solid Tumors
SYS6090 (Fixed Dose Level A) + bevacizumabOncology
Phase 2
Unresectable Advanced or Metastatic Colorectal Cancer
SYS6090 Injection + Bevacizumab InjectionOncology
Phase 2
HCC - Hepatocellular Carcinoma
ammoxetine hydrochloride enteric-coated tabletsOther
Phase 1
Participants With Mild Hepatic ImpairmentParticipants With Moderate Renal Impairment
Ammoxetine hydrochloride Enteric-coated Tablets(new formulation)Other
Phase 1
Healthy volunteers
CM326(formulation 1)Other
Phase 1
Healthy volunteers
paclitaxel cationic liposome for injectionOncology
Phase 1
Colorectal Liver Metastases
paclitaxel cationic liposomesOncology
Phase 1
Advanced Solid Tumor
Paclitaxel protein-bound particles for injectable suspension (albumin-bound)Other
Phase 1
Bioequivalence
Sirolimus (albumin - bound)Oncology
Phase 1
Advanced Breast Cancer
SYH2061Other
Phase 1
Healthy volunteers
SYH2062 injectionOther
Phase 1
Healthy volunteers
SYH2070 injectionOther
Phase 1
Healthy volunteers
SYH2082 InjectionMetabolic
Phase 1
Overweight or Obesity (2)
SYH2092 InjectionMetabolic
Phase 1
Overweight or Obesity
SYH9017Metabolic
Phase 1
Overweight or Obesity
SYH9089 injectionOther
Phase 1
Postoperative Pain
SYS6005Oncology
Phase 1
B-cell Malignancies
SYS6020Autoimmune
Phase 1
Refractory Active Systemic Lupus Erythematosus
SYS6020 injectionAutoimmune
Phase 1
Myasthenia Gravis
SYS6040 for injectionOncology
Phase 1
Small Cell Lung Cancer
SYS6051Oncology
Phase 1
Advanced Solid Tumors

Active registered Phase 1–3 trials from ClinicalTrials.gov — not the company's official IR pipeline (no preclinical or undisclosed assets). Grouped by trial intervention name; therapeutic area is auto-categorized. Each indication links to its trial. Molecular targets sourced from ChEMBL (EMBL-EBI).

Targets from a ChEMBL (EMBL-EBI) snapshot dated 2026-08-20 · 310/1701 assets resolved when it was built

See the full biopharma catalyst calendar across all covered companies.